A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, Monoclonal Antibody Against Lysyl Oxidase-Like 2 (LOXL2)
A Study of Subjects with Compensated Cirrhosis Secondary to Non-Alcoholic Steatohepatits (NASH) Study
Sponsor: Gilead Sciences Inc.
Enrolling: Male and Female Patients
IRB Number: AAAM5104
Contact: Theresa Lukose: 212-305-3839 / tt2103@columbia.edu
Additional Study Information: The purpose of this study is to evaluate whether cirrhosis occurs as a result of NASH. NASH is a disease that results when fat accumulates in the liver. GS-6624 is an experimental medication designed to help reverse the scarring process, and the purpose of this study is to see if GS-6624 can reverse the scarring in the liver and heal cirrhosis.
This study is closed
Investigator
Julia Wattacheril, MD, MPH
Do You Qualify?
Do you have cirrhosis of the liver? Yes No
Do you have clinically significant cardiac disease? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Theresa Lukose
tt2103@columbia.edu
212-305-3839
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE